| Trait Information | |
| Identifier | MONDO_0002050 |
| Description | A melancholy feeling of sadness and despair. [NCIT: C2982] | Trait category |
Neurological disorder
|
| Synonyms |
2 synonyms
|
| Mapped terms |
8 mapped terms
|
| Child trait(s) | major depressive disorder |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | Ancestry distribution | Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000138 (LifetimeMDD) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Lifetime Major Depressive Disorder | major depressive disorder | 22,274 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000138/ScoringFiles/PGS000138.txt.gz |
| PGS000139 (MDDRecur) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Lifetime Major Depressive Disorder (with recurrence) | recurrent, major depressive disorder |
21,980 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000139/ScoringFiles/PGS000139.txt.gz |
| PGS000140 (GPpsy) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Broad Depression (seen a General Practitioner for nerves, anxiety, tension or depression) | seeing a general practitioner for nerves, anxiety, tension or depression, self-reported, depressive disorder |
24,665 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000140/ScoringFiles/PGS000140.txt.gz |
| PGS000141 (Psypsy) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Seen a psychiatrist for nerves, anxiety, tension or depression | seeing a psychiatrist for nerves, anxiety, tension or depression, self-reported, depressive disorder |
22,728 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000141/ScoringFiles/PGS000141.txt.gz |
| PGS000142 (DepAll) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Probable Depression (low mood or anhedonia, and seen a GP or psychiatrist for nerves, anxiety, tension or depression) | seeing a general practitioner for nerves, anxiety, tension or depression, self-reported, seeing a psychiatrist for nerves, anxiety, tension or depression, self-reported, depressive disorder |
21,908 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000142/ScoringFiles/PGS000142.txt.gz |
| PGS000145 (ICD10Dep) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Depression (ICD-10 defined) | major depressive disorder | 21,510 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000145/ScoringFiles/PGS000145.txt.gz |
| PGS000193 (MDD_0.001_Coleman_2020) |
PGS000080 | Coleman JRI et al. Mol Psychiatry (2020) |
Major depression | major depressive disorder | 1,138 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000193/ScoringFiles/PGS000193.txt.gz |
| PGS000907 (PRS_MDD) |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Major depressive disorder | major depressive disorder | 1,773,528 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000907/ScoringFiles/PGS000907.txt.gz |
| PGS001829 (portability-PLR_296.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Depression | depressive disorder | 7,534 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001829/ScoringFiles/PGS001829.txt.gz |
| PGS002036 (portability-ldpred2_296.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Depression | depressive disorder | 807,338 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002036/ScoringFiles/PGS002036.txt.gz |
| PGS002789 (MDD_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Major depressive disorder | major depressive disorder | 943,784 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002789/ScoringFiles/PGS002789.txt.gz |
| PGS003333 (MDD-PRS) |
PGP000399 | Fang Y et al. Biol Psychiatry (2022) |
Major Depressive Disorder | major depressive disorder | 1,088,415 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003333/ScoringFiles/PGS003333.txt.gz |
| PGS003442 (GRS8_MD) |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Major depressive disorder | major depressive disorder | 8 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003442/ScoringFiles/PGS003442.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000433 | PGS000141 (Psypsy) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.52988 | R²: 0.00438 | Cohort | — |
| PPM000437 | PGS000145 (ICD10Dep) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5251 | R²: 0.0032 | Cohort | — |
| PPM000434 | PGS000142 (DepAll) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5333 | R²: 0.00492 | Cohort | — |
| PPM000432 | PGS000140 (GPpsy) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.53193 | R²: 0.00481 | Cohort | — |
| PPM000431 | PGS000139 (MDDRecur) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.54874 | R²: 0.01097 | Cohort | — |
| PPM000430 | PGS000138 (LifetimeMDD) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5611 | R²: 0.01817 | Cohort | — |
| PPM000564 | PGS000193 (MDD_0.001_Coleman_2020) |
PSS000294| European Ancestry| 92,957 individuals |
PGS000080 | Coleman JRI et al. Mol Psychiatry (2020) |
Reported Trait: Major depressive disorder | OR: 1.179 | — | R²: 0.01485 Nagelkerke pseudo-R2 (increase when adding PRS to null model of covariates): 0.00785 |
batch, centre, genomic prinicipal components (x6) | — |
| PPM002681 | PGS000907 (PRS_MDD) |
PSS001279| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Escitalopram takers | OR: 1.0 [0.92, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002682 | PGS000907 (PRS_MDD) |
PSS001284| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Venlafaxine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002684 | PGS000907 (PRS_MDD) |
PSS001281| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Mirtazapine takers | OR: 1.05 [0.91, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002685 | PGS000907 (PRS_MDD) |
PSS001277| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Desvenlafaxine takers | OR: 1.01 [0.91, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002686 | PGS000907 (PRS_MDD) |
PSS001276| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Citalopram takers | OR: 1.02 [0.9, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002687 | PGS000907 (PRS_MDD) |
PSS001280| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Fluoxetine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002688 | PGS000907 (PRS_MDD) |
PSS001278| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Duloxetine takers | OR: 1.06 [0.95, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002689 | PGS000907 (PRS_MDD) |
PSS001282| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Paroxetine takers | OR: 1.08 [0.92, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002690 | PGS000907 (PRS_MDD) |
PSS001243| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Sertraline takers | OR: 1.06 [0.98, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002691 | PGS000907 (PRS_MDD) |
PSS001239| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002692 | PGS000907 (PRS_MDD) |
PSS001244| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Venlafaxine takers | OR: 1.01 [0.93, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002693 | PGS000907 (PRS_MDD) |
PSS001235| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Amitriptyline takers | OR: 0.96 [0.83, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002694 | PGS000907 (PRS_MDD) |
PSS001241| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Mirtazapine takers | OR: 1.07 [0.93, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002695 | PGS000907 (PRS_MDD) |
PSS001237| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Desvenlafaxine takers | OR: 0.97 [0.87, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002696 | PGS000907 (PRS_MDD) |
PSS001236| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Citalopram takers | OR: 0.99 [0.87, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002697 | PGS000907 (PRS_MDD) |
PSS001240| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Fluoxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.41 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002698 | PGS000907 (PRS_MDD) |
PSS001238| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Duloxetine takers | OR: 0.98 [0.88, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002699 | PGS000907 (PRS_MDD) |
PSS001242| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dizziness in Paroxetine takers | OR: 1.08 [0.93, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002700 | PGS000907 (PRS_MDD) |
PSS001373| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Sertraline takers | OR: 1.03 [0.94, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002701 | PGS000907 (PRS_MDD) |
PSS001369| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Escitalopram takers | OR: 1.01 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002702 | PGS000907 (PRS_MDD) |
PSS001374| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Venlafaxine takers | OR: 1.1 [1.0, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002703 | PGS000907 (PRS_MDD) |
PSS001365| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Amitriptyline takers | OR: 0.99 [0.81, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002704 | PGS000907 (PRS_MDD) |
PSS001371| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Mirtazapine takers | OR: 1.03 [0.86, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002705 | PGS000907 (PRS_MDD) |
PSS001367| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Desvenlafaxine takers | OR: 1.04 [0.92, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002707 | PGS000907 (PRS_MDD) |
PSS001370| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Fluoxetine takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002708 | PGS000907 (PRS_MDD) |
PSS001368| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Duloxetine takers | OR: 0.9 [0.79, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002709 | PGS000907 (PRS_MDD) |
PSS001372| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Paroxetine takers | OR: 1.19 [1.0, 1.41] | — | Variance explained (Nagelkerke's R2*100): 0.53 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002710 | PGS000907 (PRS_MDD) |
PSS001303| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Sertraline takers | OR: 1.13 [0.97, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002711 | PGS000907 (PRS_MDD) |
PSS001299| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Escitalopram takers | OR: 0.96 [0.8, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002712 | PGS000907 (PRS_MDD) |
PSS001304| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Venlafaxine takers | OR: 1.22 [1.03, 1.45] | — | Variance explained (Nagelkerke's R2*100): 0.51 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002713 | PGS000907 (PRS_MDD) |
PSS001295| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Amitriptyline takers | OR: 1.06 [0.8, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002715 | PGS000907 (PRS_MDD) |
PSS001297| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Desvenlafaxine takers | OR: 1.0 [0.8, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002716 | PGS000907 (PRS_MDD) |
PSS001296| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Citalopram takers | OR: 0.95 [0.72, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002717 | PGS000907 (PRS_MDD) |
PSS001300| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Fluoxetine takers | OR: 1.3 [1.05, 1.6] | — | Variance explained (Nagelkerke's R2*100): 0.77 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002718 | PGS000907 (PRS_MDD) |
PSS001298| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Duloxetine takers | OR: 0.99 [0.82, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002720 | PGS000907 (PRS_MDD) |
PSS001263| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Sertraline takers | OR: 1.04 [0.98, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002721 | PGS000907 (PRS_MDD) |
PSS001259| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Escitalopram takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002722 | PGS000907 (PRS_MDD) |
PSS001264| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Venlafaxine takers | OR: 0.98 [0.91, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002723 | PGS000907 (PRS_MDD) |
PSS001255| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Amitriptyline takers | OR: 1.06 [0.95, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002724 | PGS000907 (PRS_MDD) |
PSS001261| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Mirtazapine takers | OR: 1.05 [0.94, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002725 | PGS000907 (PRS_MDD) |
PSS001257| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Desvenlafaxine takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002726 | PGS000907 (PRS_MDD) |
PSS001256| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Citalopram takers | OR: 1.11 [1.0, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.23 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002727 | PGS000907 (PRS_MDD) |
PSS001260| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Fluoxetine takers | OR: 1.0 [0.92, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002728 | PGS000907 (PRS_MDD) |
PSS001258| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Duloxetine takers | OR: 1.03 [0.93, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002729 | PGS000907 (PRS_MDD) |
PSS001262| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Dry mouth in Paroxetine takers | OR: 0.98 [0.86, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002730 | PGS000907 (PRS_MDD) |
PSS001403| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Sertraline takers | OR: 0.99 [0.92, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002731 | PGS000907 (PRS_MDD) |
PSS001399| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Escitalopram takers | OR: 0.97 [0.89, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002732 | PGS000907 (PRS_MDD) |
PSS001404| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Venlafaxine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002733 | PGS000907 (PRS_MDD) |
PSS001395| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Amitriptyline takers | OR: 1.14 [0.96, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002734 | PGS000907 (PRS_MDD) |
PSS001401| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Mirtazapine takers | OR: 1.05 [0.9, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002735 | PGS000907 (PRS_MDD) |
PSS001397| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Desvenlafaxine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002736 | PGS000907 (PRS_MDD) |
PSS001396| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Citalopram takers | OR: 1.14 [0.99, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002737 | PGS000907 (PRS_MDD) |
PSS001400| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Fluoxetine takers | OR: 1.04 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002738 | PGS000907 (PRS_MDD) |
PSS001398| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Duloxetine takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002739 | PGS000907 (PRS_MDD) |
PSS001402| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Sweating in Paroxetine takers | OR: 1.1 [0.94, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.17 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002741 | PGS000907 (PRS_MDD) |
PSS001309| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002742 | PGS000907 (PRS_MDD) |
PSS001314| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Venlafaxine takers | OR: 1.08 [1.0, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002743 | PGS000907 (PRS_MDD) |
PSS001305| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Amitriptyline takers | OR: 1.12 [0.95, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002744 | PGS000907 (PRS_MDD) |
PSS001311| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Mirtazapine takers | OR: 1.08 [0.93, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002745 | PGS000907 (PRS_MDD) |
PSS001307| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Desvenlafaxine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002746 | PGS000907 (PRS_MDD) |
PSS001306| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Citalopram takers | OR: 1.11 [0.99, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.24 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002747 | PGS000907 (PRS_MDD) |
PSS001310| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Fluoxetine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002748 | PGS000907 (PRS_MDD) |
PSS001308| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Duloxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.55 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002749 | PGS000907 (PRS_MDD) |
PSS001312| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Paroxetine takers | OR: 1.1 [0.96, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002750 | PGS000907 (PRS_MDD) |
PSS001423| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Sertraline takers | OR: 1.21 [1.03, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.44 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002751 | PGS000907 (PRS_MDD) |
PSS001419| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Escitalopram takers | OR: 0.96 [0.78, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002752 | PGS000907 (PRS_MDD) |
PSS001424| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Venlafaxine takers | OR: 1.14 [0.96, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002754 | PGS000907 (PRS_MDD) |
PSS001421| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Mirtazapine takers | OR: 1.23 [0.88, 1.72] | — | Variance explained (Nagelkerke's R2*100): 0.45 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002755 | PGS000907 (PRS_MDD) |
PSS001417| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Desvenlafaxine takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002756 | PGS000907 (PRS_MDD) |
PSS001416| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Citalopram takers | OR: 1.19 [0.87, 1.64] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002757 | PGS000907 (PRS_MDD) |
PSS001420| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Fluoxetine takers | OR: 1.01 [0.8, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002758 | PGS000907 (PRS_MDD) |
PSS001418| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Duloxetine takers | OR: 1.09 [0.87, 1.35] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002759 | PGS000907 (PRS_MDD) |
PSS001422| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Paroxetine takers | OR: 1.17 [0.86, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002760 | PGS000907 (PRS_MDD) |
PSS001223| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Sertraline takers | OR: 1.15 [1.03, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002761 | PGS000907 (PRS_MDD) |
PSS001219| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Escitalopram takers | OR: 1.16 [1.01, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002762 | PGS000907 (PRS_MDD) |
PSS001224| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Venlafaxine takers | OR: 1.19 [1.07, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002763 | PGS000907 (PRS_MDD) |
PSS001215| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Amitriptyline takers | OR: 1.16 [0.98, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.38 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002764 | PGS000907 (PRS_MDD) |
PSS001221| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Mirtazapine takers | OR: 1.08 [0.89, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002765 | PGS000907 (PRS_MDD) |
PSS001217| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Desvenlafaxine takers | OR: 1.03 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002767 | PGS000907 (PRS_MDD) |
PSS001220| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Fluoxetine takers | OR: 1.09 [0.94, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002768 | PGS000907 (PRS_MDD) |
PSS001218| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Duloxetine takers | OR: 1.02 [0.89, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002769 | PGS000907 (PRS_MDD) |
PSS001222| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Paroxetine takers | OR: 1.09 [0.9, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002771 | PGS000907 (PRS_MDD) |
PSS001229| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Escitalopram takers | OR: 1.01 [0.89, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002772 | PGS000907 (PRS_MDD) |
PSS001234| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Venlafaxine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002773 | PGS000907 (PRS_MDD) |
PSS001225| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Amitriptyline takers | OR: 1.02 [0.73, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002774 | PGS000907 (PRS_MDD) |
PSS001231| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Mirtazapine takers | OR: 1.13 [0.89, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002775 | PGS000907 (PRS_MDD) |
PSS001227| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Desvenlafaxine takers | OR: 1.01 [0.84, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002776 | PGS000907 (PRS_MDD) |
PSS001226| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Citalopram takers | OR: 0.95 [0.76, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002777 | PGS000907 (PRS_MDD) |
PSS001230| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Fluoxetine takers | OR: 0.99 [0.84, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002778 | PGS000907 (PRS_MDD) |
PSS001228| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Duloxetine takers | OR: 1.08 [0.9, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002779 | PGS000907 (PRS_MDD) |
PSS001232| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Paroxetine takers | OR: 1.47 [1.13, 1.91] | — | Variance explained (Nagelkerke's R2*100): 1.92 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002780 | PGS000907 (PRS_MDD) |
PSS001253| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002782 | PGS000907 (PRS_MDD) |
PSS001254| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Venlafaxine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002783 | PGS000907 (PRS_MDD) |
PSS001245| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Amitriptyline takers | OR: 0.99 [0.89, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002784 | PGS000907 (PRS_MDD) |
PSS001251| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Mirtazapine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002785 | PGS000907 (PRS_MDD) |
PSS001247| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Desvenlafaxine takers | OR: 0.99 [0.88, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002786 | PGS000907 (PRS_MDD) |
PSS001246| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Citalopram takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002787 | PGS000907 (PRS_MDD) |
PSS001250| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Fluoxetine takers | OR: 1.04 [0.94, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002788 | PGS000907 (PRS_MDD) |
PSS001248| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Duloxetine takers | OR: 0.96 [0.86, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002789 | PGS000907 (PRS_MDD) |
PSS001252| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Paroxetine takers | OR: 0.97 [0.83, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002790 | PGS000907 (PRS_MDD) |
PSS001413| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Sertraline takers | OR: 1.04 [0.97, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002791 | PGS000907 (PRS_MDD) |
PSS001409| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Escitalopram takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002792 | PGS000907 (PRS_MDD) |
PSS001414| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Venlafaxine takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002793 | PGS000907 (PRS_MDD) |
PSS001405| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Amitriptyline takers | OR: 1.05 [0.88, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002794 | PGS000907 (PRS_MDD) |
PSS001411| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Mirtazapine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002795 | PGS000907 (PRS_MDD) |
PSS001407| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Desvenlafaxine takers | OR: 1.05 [0.95, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002796 | PGS000907 (PRS_MDD) |
PSS001406| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Citalopram takers | OR: 1.0 [0.89, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002797 | PGS000907 (PRS_MDD) |
PSS001410| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Fluoxetine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002798 | PGS000907 (PRS_MDD) |
PSS001408| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Duloxetine takers | OR: 0.97 [0.87, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002800 | PGS000907 (PRS_MDD) |
PSS001203| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Sertraline takers | OR: 1.13 [1.04, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002801 | PGS000907 (PRS_MDD) |
PSS001199| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Escitalopram takers | OR: 1.01 [0.91, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002802 | PGS000907 (PRS_MDD) |
PSS001204| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Venlafaxine takers | OR: 1.14 [1.04, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.36 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002803 | PGS000907 (PRS_MDD) |
PSS001195| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Amitriptyline takers | OR: 1.05 [0.87, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002804 | PGS000907 (PRS_MDD) |
PSS001201| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Mirtazapine takers | OR: 1.2 [1.03, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.59 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002805 | PGS000907 (PRS_MDD) |
PSS001197| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Desvenlafaxine takers | OR: 1.04 [0.92, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002806 | PGS000907 (PRS_MDD) |
PSS001196| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Citalopram takers | OR: 0.97 [0.85, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002807 | PGS000907 (PRS_MDD) |
PSS001200| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Fluoxetine takers | OR: 1.05 [0.96, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002808 | PGS000907 (PRS_MDD) |
PSS001198| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Duloxetine takers | OR: 1.0 [0.87, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002809 | PGS000907 (PRS_MDD) |
PSS001202| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Anxiety in Paroxetine takers | OR: 1.1 [0.94, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002810 | PGS000907 (PRS_MDD) |
PSS001193| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Sertraline takers | OR: 1.04 [0.96, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002811 | PGS000907 (PRS_MDD) |
PSS001189| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Escitalopram takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002812 | PGS000907 (PRS_MDD) |
PSS001194| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Venlafaxine takers | OR: 1.06 [0.97, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002813 | PGS000907 (PRS_MDD) |
PSS001185| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Amitriptyline takers | OR: 1.02 [0.85, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002814 | PGS000907 (PRS_MDD) |
PSS001191| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Mirtazapine takers | OR: 1.25 [1.08, 1.46] | — | Variance explained (Nagelkerke's R2*100): 0.93 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002816 | PGS000907 (PRS_MDD) |
PSS001186| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Citalopram takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002817 | PGS000907 (PRS_MDD) |
PSS001190| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Fluoxetine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002818 | PGS000907 (PRS_MDD) |
PSS001188| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Duloxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002819 | PGS000907 (PRS_MDD) |
PSS001192| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Paroxetine takers | OR: 1.19 [1.02, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002820 | PGS000907 (PRS_MDD) |
PSS001273| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002821 | PGS000907 (PRS_MDD) |
PSS001269| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Escitalopram takers | OR: 0.96 [0.88, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002822 | PGS000907 (PRS_MDD) |
PSS001274| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Venlafaxine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002823 | PGS000907 (PRS_MDD) |
PSS001265| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Amitriptyline takers | OR: 1.12 [0.97, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002824 | PGS000907 (PRS_MDD) |
PSS001271| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Mirtazapine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002826 | PGS000907 (PRS_MDD) |
PSS001266| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Citalopram takers | OR: 0.98 [0.86, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002827 | PGS000907 (PRS_MDD) |
PSS001270| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Fluoxetine takers | OR: 1.02 [0.92, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002829 | PGS000907 (PRS_MDD) |
PSS001272| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Paroxetine takers | OR: 0.96 [0.82, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002831 | PGS000907 (PRS_MDD) |
PSS001429| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Escitalopram takers | OR: 1.04 [0.97, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002832 | PGS000907 (PRS_MDD) |
PSS001434| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Venlafaxine takers | OR: 1.03 [0.96, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002833 | PGS000907 (PRS_MDD) |
PSS001425| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Amitriptyline takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002834 | PGS000907 (PRS_MDD) |
PSS001431| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Mirtazapine takers | OR: 1.02 [0.93, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002835 | PGS000907 (PRS_MDD) |
PSS001427| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Desvenlafaxine takers | OR: 1.11 [1.02, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.33 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002836 | PGS000907 (PRS_MDD) |
PSS001426| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Citalopram takers | OR: 1.14 [1.03, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.4 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002837 | PGS000907 (PRS_MDD) |
PSS001430| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Fluoxetine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002838 | PGS000907 (PRS_MDD) |
PSS001428| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Duloxetine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002839 | PGS000907 (PRS_MDD) |
PSS001432| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Paroxetine takers | OR: 1.11 [0.99, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002840 | PGS000907 (PRS_MDD) |
PSS001443| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Sertraline takers | OR: 0.9 [0.75, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002841 | PGS000907 (PRS_MDD) |
PSS001439| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Escitalopram takers | OR: 1.07 [0.88, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002842 | PGS000907 (PRS_MDD) |
PSS001444| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Venlafaxine takers | OR: 1.05 [0.84, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002844 | PGS000907 (PRS_MDD) |
PSS001441| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Mirtazapine takers | OR: 1.21 [0.85, 1.71] | — | Variance explained (Nagelkerke's R2*100): 0.37 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002845 | PGS000907 (PRS_MDD) |
PSS001437| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Desvenlafaxine takers | OR: 0.95 [0.74, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002846 | PGS000907 (PRS_MDD) |
PSS001436| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Citalopram takers | OR: 0.87 [0.61, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002847 | PGS000907 (PRS_MDD) |
PSS001440| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Fluoxetine takers | OR: 1.16 [0.96, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.26 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002848 | PGS000907 (PRS_MDD) |
PSS001438| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Duloxetine takers | OR: 0.96 [0.75, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002849 | PGS000907 (PRS_MDD) |
PSS001442| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Paroxetine takers | OR: 1.36 [0.88, 2.1] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002852 | PGS000907 (PRS_MDD) |
PSS001344| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Venlafaxine takers | OR: 1.0 [0.74, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002853 | PGS000907 (PRS_MDD) |
PSS001335| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Amitriptyline takers | OR: 1.22 [0.73, 2.04] | — | Variance explained (Nagelkerke's R2*100): 0.42 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002854 | PGS000907 (PRS_MDD) |
PSS001341| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Mirtazapine takers | OR: 1.0 [0.65, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002855 | PGS000907 (PRS_MDD) |
PSS001337| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Desvenlafaxine takers | OR: 1.58 [1.13, 2.23] | — | Variance explained (Nagelkerke's R2*100): 2.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002856 | PGS000907 (PRS_MDD) |
PSS001336| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Citalopram takers | OR: 1.1 [0.7, 1.74] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002857 | PGS000907 (PRS_MDD) |
PSS001340| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Fluoxetine takers | OR: 1.34 [0.91, 1.97] | — | Variance explained (Nagelkerke's R2*100): 0.75 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002858 | PGS000907 (PRS_MDD) |
PSS001338| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Duloxetine takers | OR: 1.13 [0.75, 1.7] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002859 | PGS000907 (PRS_MDD) |
PSS001342| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Paroxetine takers | OR: 1.16 [0.69, 1.95] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002860 | PGS000907 (PRS_MDD) |
PSS001363| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Sertraline takers | OR: 1.0 [0.79, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002861 | PGS000907 (PRS_MDD) |
PSS001359| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Escitalopram takers | OR: 0.91 [0.69, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002862 | PGS000907 (PRS_MDD) |
PSS001364| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Venlafaxine takers | OR: 1.06 [0.8, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002863 | PGS000907 (PRS_MDD) |
PSS001355| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Amitriptyline takers | OR: 0.59 [0.36, 0.98] | — | Variance explained (Nagelkerke's R2*100): 2.43 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002864 | PGS000907 (PRS_MDD) |
PSS001361| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Mirtazapine takers | OR: 0.85 [0.55, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002865 | PGS000907 (PRS_MDD) |
PSS001357| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Desvenlafaxine takers | OR: 0.8 [0.59, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.58 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002868 | PGS000907 (PRS_MDD) |
PSS001358| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Duloxetine takers | OR: 0.99 [0.71, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002869 | PGS000907 (PRS_MDD) |
PSS001362| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Paroxetine takers | OR: 0.9 [0.53, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002870 | PGS000907 (PRS_MDD) |
PSS001353| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Sertraline takers | OR: 1.0 [0.95, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002871 | PGS000907 (PRS_MDD) |
PSS001349| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Escitalopram takers | OR: 0.99 [0.93, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002872 | PGS000907 (PRS_MDD) |
PSS001354| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Venlafaxine takers | OR: 1.05 [0.99, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002873 | PGS000907 (PRS_MDD) |
PSS001345| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Amitriptyline takers | OR: 1.08 [0.96, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.16 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002878 | PGS000907 (PRS_MDD) |
PSS001348| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Duloxetine takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002879 | PGS000907 (PRS_MDD) |
PSS001352| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Paroxetine takers | OR: 1.0 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002883 | PGS000907 (PRS_MDD) |
PSS001205| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Amitriptyline takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002884 | PGS000907 (PRS_MDD) |
PSS001211| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Mirtazapine takers | OR: 1.05 [0.84, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002885 | PGS000907 (PRS_MDD) |
PSS001207| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Desvenlafaxine takers | OR: 1.13 [0.94, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002886 | PGS000907 (PRS_MDD) |
PSS001206| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Citalopram takers | OR: 1.39 [1.08, 1.79] | — | Variance explained (Nagelkerke's R2*100): 1.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002887 | PGS000907 (PRS_MDD) |
PSS001210| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Fluoxetine takers | OR: 1.03 [0.85, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002888 | PGS000907 (PRS_MDD) |
PSS001208| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Duloxetine takers | OR: 1.04 [0.87, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002889 | PGS000907 (PRS_MDD) |
PSS001212| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Paroxetine takers | OR: 1.32 [1.0, 1.75] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002890 | PGS000907 (PRS_MDD) |
PSS001393| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Sertraline takers | OR: 1.24 [1.14, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.9 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002894 | PGS000907 (PRS_MDD) |
PSS001391| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Mirtazapine takers | OR: 1.09 [0.94, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002895 | PGS000907 (PRS_MDD) |
PSS001387| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Desvenlafaxine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002896 | PGS000907 (PRS_MDD) |
PSS001386| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Citalopram takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002897 | PGS000907 (PRS_MDD) |
PSS001390| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Fluoxetine takers | OR: 1.12 [1.02, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002898 | PGS000907 (PRS_MDD) |
PSS001388| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Duloxetine takers | OR: 0.98 [0.86, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002899 | PGS000907 (PRS_MDD) |
PSS001392| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Paroxetine takers | OR: 1.22 [1.05, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.8 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002900 | PGS000907 (PRS_MDD) |
PSS001383| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Sertraline takers | OR: 1.15 [1.01, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002901 | PGS000907 (PRS_MDD) |
PSS001379| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Escitalopram takers | OR: 1.06 [0.9, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002902 | PGS000907 (PRS_MDD) |
PSS001384| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Venlafaxine takers | OR: 1.36 [1.18, 1.58] | — | Variance explained (Nagelkerke's R2*100): 1.35 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002903 | PGS000907 (PRS_MDD) |
PSS001375| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Amitriptyline takers | OR: 0.97 [0.75, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002904 | PGS000907 (PRS_MDD) |
PSS001381| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Mirtazapine takers | OR: 1.11 [0.88, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002905 | PGS000907 (PRS_MDD) |
PSS001377| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Desvenlafaxine takers | OR: 0.97 [0.78, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002906 | PGS000907 (PRS_MDD) |
PSS001376| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Citalopram takers | OR: 0.96 [0.76, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002907 | PGS000907 (PRS_MDD) |
PSS001380| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Fluoxetine takers | OR: 1.09 [0.95, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002908 | PGS000907 (PRS_MDD) |
PSS001378| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Duloxetine takers | OR: 1.11 [0.89, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002909 | PGS000907 (PRS_MDD) |
PSS001382| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide attempt in Paroxetine takers | OR: 1.22 [0.95, 1.55] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002910 | PGS000907 (PRS_MDD) |
PSS001333| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Sertraline takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002911 | PGS000907 (PRS_MDD) |
PSS001329| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Escitalopram takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002912 | PGS000907 (PRS_MDD) |
PSS001334| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Venlafaxine takers | OR: 1.14 [1.03, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.31 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002913 | PGS000907 (PRS_MDD) |
PSS001325| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Amitriptyline takers | OR: 1.07 [0.88, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002914 | PGS000907 (PRS_MDD) |
PSS001331| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Mirtazapine takers | OR: 1.03 [0.87, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002915 | PGS000907 (PRS_MDD) |
PSS001327| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Desvenlafaxine takers | OR: 1.02 [0.88, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002916 | PGS000907 (PRS_MDD) |
PSS001326| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Citalopram takers | OR: 0.95 [0.82, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002917 | PGS000907 (PRS_MDD) |
PSS001330| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Fluoxetine takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002918 | PGS000907 (PRS_MDD) |
PSS001328| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Duloxetine takers | OR: 1.04 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002919 | PGS000907 (PRS_MDD) |
PSS001332| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Other side effects in Paroxetine takers | OR: 0.97 [0.81, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002920 | PGS000907 (PRS_MDD) |
PSS001323| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Sertraline takers | OR: 1.04 [0.89, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002921 | PGS000907 (PRS_MDD) |
PSS001319| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Escitalopram takers | OR: 1.04 [0.89, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002922 | PGS000907 (PRS_MDD) |
PSS001324| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Venlafaxine takers | OR: 0.94 [0.79, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002923 | PGS000907 (PRS_MDD) |
PSS001315| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Amitriptyline takers | OR: 1.03 [0.84, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002924 | PGS000907 (PRS_MDD) |
PSS001321| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Mirtazapine takers | OR: 1.05 [0.83, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002925 | PGS000907 (PRS_MDD) |
PSS001317| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Desvenlafaxine takers | OR: 0.82 [0.68, 0.98] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002680 | PGS000907 (PRS_MDD) |
PSS001283| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Sertraline takers | OR: 1.03 [0.95, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002683 | PGS000907 (PRS_MDD) |
PSS001275| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Headaches in Amitriptyline takers | OR: 0.96 [0.81, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002706 | PGS000907 (PRS_MDD) |
PSS001366| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Shakes in Citalopram takers | OR: 1.16 [0.98, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002714 | PGS000907 (PRS_MDD) |
PSS001301| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Mirtazapine takers | OR: 1.13 [0.9, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002719 | PGS000907 (PRS_MDD) |
PSS001302| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Muscle pain in Paroxetine takers | OR: 1.18 [0.87, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002740 | PGS000907 (PRS_MDD) |
PSS001313| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Nausea in Sertraline takers | OR: 1.08 [1.01, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.13 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002753 | PGS000907 (PRS_MDD) |
PSS001415| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Vomit in Amitriptyline takers | OR: 0.93 [0.65, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002766 | PGS000907 (PRS_MDD) |
PSS001216| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Constipation in Citalopram takers | OR: 1.02 [0.85, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002770 | PGS000907 (PRS_MDD) |
PSS001233| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Diarrhoea in Sertraline takers | OR: 1.05 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002781 | PGS000907 (PRS_MDD) |
PSS001249| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Drowsiness in Escitalopram takers | OR: 0.96 [0.89, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002799 | PGS000907 (PRS_MDD) |
PSS001412| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Trouble sleeping in Paroxetine takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002815 | PGS000907 (PRS_MDD) |
PSS001187| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Agitation in Desvenlafaxine takers | OR: 1.07 [0.94, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002825 | PGS000907 (PRS_MDD) |
PSS001267| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Desvenlafaxine takers | OR: 1.02 [0.91, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002828 | PGS000907 (PRS_MDD) |
PSS001268| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Fatigue in Duloxetine takers | OR: 0.93 [0.83, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002830 | PGS000907 (PRS_MDD) |
PSS001433| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight gain in Sertraline takers | OR: 1.02 [0.96, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002843 | PGS000907 (PRS_MDD) |
PSS001435| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Weight loss in Amitriptyline takers | OR: 1.09 [0.67, 1.78] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002850 | PGS000907 (PRS_MDD) |
PSS001343| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Sertraline takers | OR: 1.04 [0.8, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002851 | PGS000907 (PRS_MDD) |
PSS001339| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Rashes in Escitalopram takers | OR: 1.09 [0.79, 1.5] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002866 | PGS000907 (PRS_MDD) |
PSS001356| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Citalopram takers | OR: 1.05 [0.73, 1.51] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002867 | PGS000907 (PRS_MDD) |
PSS001360| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Runny nose in Fluoxetine takers | OR: 1.03 [0.76, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002874 | PGS000907 (PRS_MDD) |
PSS001351| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Mirtazapine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002875 | PGS000907 (PRS_MDD) |
PSS001347| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Desvenlafaxine takers | OR: 1.11 [1.02, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002876 | PGS000907 (PRS_MDD) |
PSS001346| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Citalopram takers | OR: 1.1 [1.01, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002877 | PGS000907 (PRS_MDD) |
PSS001350| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Reduced sexual desire in Fluoxetine takers | OR: 1.05 [0.98, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002880 | PGS000907 (PRS_MDD) |
PSS001213| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Sertraline takers | OR: 0.96 [0.83, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002881 | PGS000907 (PRS_MDD) |
PSS001209| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Escitalopram takers | OR: 1.03 [0.87, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002882 | PGS000907 (PRS_MDD) |
PSS001214| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Blurry vision in Venlafaxine takers | OR: 0.97 [0.84, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002891 | PGS000907 (PRS_MDD) |
PSS001389| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Escitalopram takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002892 | PGS000907 (PRS_MDD) |
PSS001394| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Venlafaxine takers | OR: 1.19 [1.09, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.63 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002893 | PGS000907 (PRS_MDD) |
PSS001385| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: Suicide thoughts in Amitriptyline takers | OR: 0.94 [0.8, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002926 | PGS000907 (PRS_MDD) |
PSS001316| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Citalopram takers | OR: 1.08 [0.92, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002927 | PGS000907 (PRS_MDD) |
PSS001320| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Fluoxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002928 | PGS000907 (PRS_MDD) |
PSS001318| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Duloxetine takers | OR: 0.91 [0.74, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002929 | PGS000907 (PRS_MDD) |
PSS001322| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. medRxiv (2021) |Pre |
Reported Trait: No side effects in Paroxetine takers | OR: 0.97 [0.77, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM009528 | PGS001829 (portability-PLR_296.2) |
PSS008401| Greater Middle Eastern Ancestry| 1,055 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0527 [-0.0082, 0.1133] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009529 | PGS001829 (portability-PLR_296.2) |
PSS008181| South Asian Ancestry| 5,870 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): -0.0051 [-0.0307, 0.0205] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009531 | PGS001829 (portability-PLR_296.2) |
PSS007747| African Ancestry| 2,272 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): -0.0294 [-0.0706, 0.0119] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009532 | PGS001829 (portability-PLR_296.2) |
PSS008851| African Ancestry| 3,678 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0034 [-0.029, 0.0358] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009525 | PGS001829 (portability-PLR_296.2) |
PSS009299| European Ancestry| 17,764 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0323 [0.0176, 0.047] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009526 | PGS001829 (portability-PLR_296.2) |
PSS009073| European Ancestry| 3,729 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0074 [-0.0248, 0.0396] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009527 | PGS001829 (portability-PLR_296.2) |
PSS008627| European Ancestry| 5,989 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.027 [0.0017, 0.0524] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011155 | PGS002036 (portability-ldpred2_296.2) |
PSS009299| European Ancestry| 17,764 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0556 [0.041, 0.0703] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011156 | PGS002036 (portability-ldpred2_296.2) |
PSS009073| European Ancestry| 3,729 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0583 [0.0261, 0.0903] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011158 | PGS002036 (portability-ldpred2_296.2) |
PSS008401| Greater Middle Eastern Ancestry| 1,055 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0239 [-0.0371, 0.0847] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011159 | PGS002036 (portability-ldpred2_296.2) |
PSS008181| South Asian Ancestry| 5,870 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0224 [-0.0033, 0.048] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011160 | PGS002036 (portability-ldpred2_296.2) |
PSS007966| East Asian Ancestry| 1,742 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0549 [0.0077, 0.1019] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011161 | PGS002036 (portability-ldpred2_296.2) |
PSS007747| African Ancestry| 2,272 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0029 [-0.0384, 0.0442] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011162 | PGS002036 (portability-ldpred2_296.2) |
PSS008851| African Ancestry| 3,678 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0178 [-0.0147, 0.0501] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009530 | PGS001829 (portability-PLR_296.2) |
PSS007966| East Asian Ancestry| 1,742 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0274 [-0.0199, 0.0745] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011157 | PGS002036 (portability-ldpred2_296.2) |
PSS008627| European Ancestry| 5,989 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0415 [0.0162, 0.0668] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM017180 | PGS003442 (GRS8_MD) |
PSS010155| Ancestry Not Reported| 117 individuals |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Reported Trait: Fluid cognition via average SST BOLD activation in adoptees | β: 0.064 (0.027) | — | — | — | — |
| PPM017181 | PGS003442 (GRS8_MD) |
PSS010156| Ancestry Not Reported| 4,382 individuals |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Reported Trait: Fluid cognition via verage SST BOLD activation in non-adoptees | β: 0.0 (0.004) | — | — | — | — |
| PPM015246 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (rule breaking) | — | — | partial R²: 0.00268 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015300 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Cognitive total) | — | — | partial R²: 0.00106 | age, PCs1-3 | — |
| PPM015241 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (withdrawn) | — | — | partial R²: 0.00533 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015242 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (somatic symptoms) | — | — | partial R²: 0.00626 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015243 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (social problems) | — | — | partial R²: 0.00358 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015244 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (thought problems) | — | — | partial R²: 0.00276 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015247 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (aggressive behaviour) | — | — | partial R²: 0.00203 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015248 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (internalising) | — | — | partial R²: 0.00815 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015249 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (externalising) | — | — | partial R²: 0.00246 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015250 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (total problems) | — | — | partial R²: 0.00528 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015251 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 depression) | — | — | partial R²: 0.00752 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015252 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 anxety disorder) | — | — | partial R²: 0.00657 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015253 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 somatic problem) | — | — | partial R²: 0.00516 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015254 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 adhd) | — | — | partial R²: 0.00088 | age, PCs1-3 | — |
| PPM015255 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 opppsit) | — | — | partial R²: 0.00172 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015256 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 conduct) | — | — | partial R²: 0.00205 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015257 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Sluggish cognitive tempo) | — | — | partial R²: 0.0067 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015258 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Obsessive compulsive disorder) | — | — | partial R²: 0.00297 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015259 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (stress) | — | — | partial R²: 0.00464 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015260 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Picture vocabulary) | — | — | partial R²: 0.00077 | age, PCs1-3 | — |
| PPM015261 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Flanker test) | — | — | partial R²: 7e-05 | age, PCs1-3 | — |
| PPM015262 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (list sorting) | — | — | partial R²: 0.00112 | age, PCs1-3 | — |
| PPM015263 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (card sorting) | — | — | partial R²: 0.00064 | age, PCs1-3 | — |
| PPM015264 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (pattern comparison) | — | — | partial R²: 0.00012 | age, PCs1-3 | — |
| PPM015265 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Picture sequence) | — | — | partial R²: 0.00045 | age, PCs1-3 | — |
| PPM015266 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (reading) | — | — | partial R²: 0.00281 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015267 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (fluid composite) | — | — | partial R²: 0.00047 | age, PCs1-3 | — |
| PPM015268 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Crystallized composite) | — | — | partial R²: 0.00222 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015269 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Cognitive total) | — | — | partial R²: 0.00155 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015270 | PGS002789 (MDD_SDPR) |
PSS009953| European Ancestry| 68,614 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (fluid composite) | — | — | partial R²: 0.00137 | age, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015271 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (anxious/depressed) | — | — | partial R²: 0.00213 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015272 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (withdrawn) | — | — | partial R²: 0.00201 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015273 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (somatic symptoms) | — | — | partial R²: 0.00469 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015274 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (social problems) | — | — | partial R²: 0.00414 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015275 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (thought problems) | — | — | partial R²: 0.00322 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015276 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (attention problems) | — | — | partial R²: 0.00218 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015277 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (rule breaking) | — | — | partial R²: 0.00165 | age, PCs1-3 | — |
| PPM015279 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (internalising) | — | — | partial R²: 0.00397 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015280 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (externalising) | — | — | partial R²: 0.00439 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015281 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (total problems) | — | — | partial R²: 0.00566 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015282 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 depression) | — | — | partial R²: 0.00515 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015283 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 anxety disorder) | — | — | partial R²: 0.00335 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015284 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 somatic problem) | — | — | partial R²: 0.00266 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015285 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 adhd) | — | — | partial R²: 0.00154 | age, PCs1-3 | — |
| PPM015286 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 opppsit) | — | — | partial R²: 0.00642 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015287 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Dsm5 conduct) | — | — | partial R²: 0.00155 | age, PCs1-3 | — |
| PPM015288 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Sluggish cognitive tempo) | — | — | partial R²: 0.00254 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015289 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (Obsessive compulsive disorder) | — | — | partial R²: 0.00049 | age, PCs1-3 | — |
| PPM015290 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (stress) | — | — | partial R²: 0.0055 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015291 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Picture vocabulary) | — | — | partial R²: 0.00143 | age, PCs1-3 | — |
| PPM015292 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Flanker test) | — | — | partial R²: 0.00019 | age, PCs1-3 | — |
| PPM015293 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (list sorting) | — | — | partial R²: 0.00068 | age, PCs1-3 | — |
| PPM015294 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (card sorting) | — | — | partial R²: 6e-05 | age, PCs1-3 | — |
| PPM015295 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (pattern comparison) | — | — | partial R²: 5e-05 | age, PCs1-3 | — |
| PPM015296 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Picture sequence) | — | — | partial R²: 0.00048 | age, PCs1-3 | — |
| PPM015297 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (reading) | — | — | partial R²: 0.00014 | age, PCs1-3 | — |
| PPM015301 | PGS002789 (MDD_SDPR) |
PSS009951| European Ancestry| 78,561 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (fluid composite) | — | — | partial R²: 0.00137 | age, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015422 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Genu of corpus callosum | — | — | partial R²: 0.00139 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015423 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Body of corpus callosum | — | — | partial R²: 0.00095 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015424 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior limb of internal capsule R | — | — | partial R²: 0.00161 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015425 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior limb of internal capsule L | — | — | partial R²: 0.00093 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015426 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Posterior limb of internal capsule R | — | — | partial R²: 0.0008 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015427 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior corona radiata R | — | — | partial R²: 0.00087 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015428 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior corona radiata L | — | — | partial R²: 0.00092 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015429 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cingulum cingulate gyrus R | — | — | partial R²: 0.00105 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015430 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior frontooccipital fasciculus R | — | — | partial R²: 0.00096 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015431 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Genu of corpus callosum | — | — | partial R²: 0.00106 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015432 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Body of corpus callosum | — | — | partial R²: 0.00123 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015433 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior limb of internal capsule R | — | — | partial R²: 0.00155 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015434 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior corona radiata R | — | — | partial R²: 0.00097 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015435 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior corona radiata L | — | — | partial R²: 0.00097 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015436 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior corona radiata R | — | — | partial R²: 0.00146 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015437 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior corona radiata L | — | — | partial R²: 0.00099 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015438 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior longitudinal fasciculus R | — | — | partial R²: 0.00094 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015439 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior longitudinal fasciculus L | — | — | partial R²: 0.00109 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015440 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior frontooccipital fasciculus R | — | — | partial R²: 0.00081 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015441 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Anterior thalamic radiation right | — | — | partial R²: 0.00102 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015442 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Forceps minor | — | — | partial R²: 0.00115 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015443 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior longitudinal fasciculus L | — | — | partial R²: 0.00099 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015444 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Superior thalamic radiation R | — | — | partial R²: 0.00131 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015445 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: ICA component_83 | — | — | partial R²: 0.00079 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015446 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: ICA component_104 | — | — | partial R²: 0.00119 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015447 | PGS002789 (MDD_SDPR) |
PSS009952| European Ancestry| 10,343 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: ICA component_202 | — | — | partial R²: 0.00058 | age, headsize scaling factor, PCs1-10 | the observed partial R² were higher than random R²s |
| PPM015240 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (anxious/depressed) | — | — | partial R²: 0.00486 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015245 | PGS002789 (MDD_SDPR) |
PSS009950| European Ancestry| 2,524 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (attention problems) | — | — | partial R²: 0.00211 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015278 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Psychiatric behavior (aggressive behaviour) | — | — | partial R²: 0.00498 | age, PCs1-3 | the observed partial R² were higher than random R²s |
| PPM015298 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (fluid composite) | — | — | partial R²: 0.00067 | age, PCs1-3 | — |
| PPM015299 | PGS002789 (MDD_SDPR) |
PSS009949| European Ancestry| 2,198 individuals |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Reported Trait: Cognitive function (Crystallized composite) | — | — | partial R²: 0.00088 | age, PCs1-3 | — |
| PPM016144 | PGS003333 (MDD-PRS) |
PSS010048| European Ancestry| 34,703 individuals |
PGP000399 | Fang Y et al. Biol Psychiatry (2022) |
Reported Trait: Major Depressive Disorder | — | — | Nagelkerke pseudo-R2: 0.022 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS009949 | NIH Toolbox was used to measure cognition in ABCD. Children’s problems and competencies were rated using the parent-reported Children Behavior Checklist (CBCL). Details of the ABCD MRI data acquisition and analysis have been published previously. | — | 2,198 individuals, 0.0 % Male samples |
Mean = 9.89 years Sd = 0.61 years |
European | — | ABCD | — |
| PSS007747 | — | — | 2,272 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS008181 | — | — | 5,870 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS000294 | Participants completed an online follow-up questionnaire assessing common mental health disorders, including MDD symptoms. Phenotypes were derived from this questionnaire. Individuals with probable MDD met lifetime criteria based on their responses to questions derived from the Composite International Diagnostic Interview. We excluded cases if they self-reported diagnoses of schizophrenia, other psychoses, or bipolar disorder. Controls were excluded if they self-reported any mental illness, taking any drug with an antidepressant indication, or had been hospitalised with a mood disorder or met previously-defined criteria for a mood disorder. | — | [ ,
45.0 % Male samples |
Range = [46.0, 80.0] years | European | — | UKB | — |
| PSS010155 | — | — | 117 individuals, 50.0 % Male samples |
Mean = 9.96 years | Not reported | — | NR | ABCD |
| PSS007966 | — | — | 1,742 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS010048 | phecode 296.22 | — | [
|
— | European | — | MGI | — |
| PSS001185 | — | — | [
|
— | European | — | AGDS | — |
| PSS001186 | — | — | [
|
— | European | — | AGDS | — |
| PSS001187 | — | — | [
|
— | European | — | AGDS | — |
| PSS001188 | — | — | [
|
— | European | — | AGDS | — |
| PSS001189 | — | — | [
|
— | European | — | AGDS | — |
| PSS001190 | — | — | [
|
— | European | — | AGDS | — |
| PSS001191 | — | — | [
|
— | European | — | AGDS | — |
| PSS001192 | — | — | [
|
— | European | — | AGDS | — |
| PSS001193 | — | — | [
|
— | European | — | AGDS | — |
| PSS001194 | — | — | [
|
— | European | — | AGDS | — |
| PSS001195 | — | — | [
|
— | European | — | AGDS | — |
| PSS001196 | — | — | [
|
— | European | — | AGDS | — |
| PSS001197 | — | — | [
|
— | European | — | AGDS | — |
| PSS001198 | — | — | [
|
— | European | — | AGDS | — |
| PSS001199 | — | — | [
|
— | European | — | AGDS | — |
| PSS001200 | — | — | [
|
— | European | — | AGDS | — |
| PSS001201 | — | — | [
|
— | European | — | AGDS | — |
| PSS001202 | — | — | [
|
— | European | — | AGDS | — |
| PSS001203 | — | — | [
|
— | European | — | AGDS | — |
| PSS001204 | — | — | [
|
— | European | — | AGDS | — |
| PSS001205 | — | — | [
|
— | European | — | AGDS | — |
| PSS001206 | — | — | [
|
— | European | — | AGDS | — |
| PSS001207 | — | — | [
|
— | European | — | AGDS | — |
| PSS001208 | — | — | [
|
— | European | — | AGDS | — |
| PSS001209 | — | — | [
|
— | European | — | AGDS | — |
| PSS001210 | — | — | [
|
— | European | — | AGDS | — |
| PSS001211 | — | — | [
|
— | European | — | AGDS | — |
| PSS001212 | — | — | [
|
— | European | — | AGDS | — |
| PSS001213 | — | — | [
|
— | European | — | AGDS | — |
| PSS001214 | — | — | [
|
— | European | — | AGDS | — |
| PSS001215 | — | — | [
|
— | European | — | AGDS | — |
| PSS001216 | — | — | [
|
— | European | — | AGDS | — |
| PSS001217 | — | — | [
|
— | European | — | AGDS | — |
| PSS001218 | — | — | [
|
— | European | — | AGDS | — |
| PSS001219 | — | — | [
|
— | European | — | AGDS | — |
| PSS001220 | — | — | [
|
— | European | — | AGDS | — |
| PSS001221 | — | — | [
|
— | European | — | AGDS | — |
| PSS001222 | — | — | [
|
— | European | — | AGDS | — |
| PSS001223 | — | — | [
|
— | European | — | AGDS | — |
| PSS001224 | — | — | [
|
— | European | — | AGDS | — |
| PSS001225 | — | — | [
|
— | European | — | AGDS | — |
| PSS001226 | — | — | [
|
— | European | — | AGDS | — |
| PSS001227 | — | — | [
|
— | European | — | AGDS | — |
| PSS001228 | — | — | [
|
— | European | — | AGDS | — |
| PSS001229 | — | — | [
|
— | European | — | AGDS | — |
| PSS001230 | — | — | [
|
— | European | — | AGDS | — |
| PSS001231 | — | — | [
|
— | European | — | AGDS | — |
| PSS001232 | — | — | [
|
— | European | — | AGDS | — |
| PSS001233 | — | — | [
|
— | European | — | AGDS | — |
| PSS001234 | — | — | [
|
— | European | — | AGDS | — |
| PSS001235 | — | — | [
|
— | European | — | AGDS | — |
| PSS001236 | — | — | [
|
— | European | — | AGDS | — |
| PSS001237 | — | — | [
|
— | European | — | AGDS | — |
| PSS001238 | — | — | [
|
— | European | — | AGDS | — |
| PSS001239 | — | — | [
|
— | European | — | AGDS | — |
| PSS001240 | — | — | [
|
— | European | — | AGDS | — |
| PSS001241 | — | — | [
|
— | European | — | AGDS | — |
| PSS001242 | — | — | [
|
— | European | — | AGDS | — |
| PSS001243 | — | — | [
|
— | European | — | AGDS | — |
| PSS001244 | — | — | [
|
— | European | — | AGDS | — |
| PSS001245 | — | — | [
|
— | European | — | AGDS | — |
| PSS001246 | — | — | [
|
— | European | — | AGDS | — |
| PSS001247 | — | — | [
|
— | European | — | AGDS | — |
| PSS001248 | — | — | [
|
— | European | — | AGDS | — |
| PSS001249 | — | — | [
|
— | European | — | AGDS | — |
| PSS001250 | — | — | [
|
— | European | — | AGDS | — |
| PSS001251 | — | — | [
|
— | European | — | AGDS | — |
| PSS001252 | — | — | [
|
— | European | — | AGDS | — |
| PSS001253 | — | — | [
|
— | European | — | AGDS | — |
| PSS001254 | — | — | [
|
— | European | — | AGDS | — |
| PSS001255 | — | — | [
|
— | European | — | AGDS | — |
| PSS001256 | — | — | [
|
— | European | — | AGDS | — |
| PSS001257 | — | — | [
|
— | European | — | AGDS | — |
| PSS001258 | — | — | [
|
— | European | — | AGDS | — |
| PSS001259 | — | — | [
|
— | European | — | AGDS | — |
| PSS001260 | — | — | [
|
— | European | — | AGDS | — |
| PSS001261 | — | — | [
|
— | European | — | AGDS | — |
| PSS001262 | — | — | [
|
— | European | — | AGDS | — |
| PSS001263 | — | — | [
|
— | European | — | AGDS | — |
| PSS001264 | — | — | [
|
— | European | — | AGDS | — |
| PSS001265 | — | — | [
|
— | European | — | AGDS | — |
| PSS001266 | — | — | [
|
— | European | — | AGDS | — |
| PSS001267 | — | — | [
|
— | European | — | AGDS | — |
| PSS001268 | — | — | [
|
— | European | — | AGDS | — |
| PSS001269 | — | — | [
|
— | European | — | AGDS | — |
| PSS001270 | — | — | [
|
— | European | — | AGDS | — |
| PSS001271 | — | — | [
|
— | European | — | AGDS | — |
| PSS001272 | — | — | [
|
— | European | — | AGDS | — |
| PSS001273 | — | — | [
|
— | European | — | AGDS | — |
| PSS001274 | — | — | [
|
— | European | — | AGDS | — |
| PSS001275 | — | — | [
|
— | European | — | AGDS | — |
| PSS001276 | — | — | [
|
— | European | — | AGDS | — |
| PSS001277 | — | — | [
|
— | European | — | AGDS | — |
| PSS001278 | — | — | [
|
— | European | — | AGDS | — |
| PSS001279 | — | — | [
|
— | European | — | AGDS | — |
| PSS001280 | — | — | [
|
— | European | — | AGDS | — |
| PSS001281 | — | — | [
|
— | European | — | AGDS | — |
| PSS001282 | — | — | [
|
— | European | — | AGDS | — |
| PSS001283 | — | — | [
|
— | European | — | AGDS | — |
| PSS001284 | — | — | [
|
— | European | — | AGDS | — |
| PSS008851 | — | — | 3,678 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS009950 | NIH Toolbox was used to measure cognition in ABCD. Children’s problems and competencies were rated using the parent-reported Children Behavior Checklist (CBCL). Details of the ABCD MRI data acquisition and analysis have been published previously. | — | 2,524 individuals, 100.0 % Male samples |
Mean = 9.92 years Sd = 0.62 years |
European | — | ABCD | — |
| PSS009951 | Fluid intelligence test | — | 78,561 individuals, 0.0 % Male samples |
Mean = 57.46 years Sd = 8.08 years |
European | — | UKB | — |
| PSS009952 | imaging-derived phenotypes (IDPs) generated by an image-processing pipeline developed and ran on behalf of the UKB | — | 10,343 individuals, 0.0 % Male samples |
Mean = 63.13 years Sd = 7.3 years |
European | — | UKB | — |
| PSS009953 | Fluid intelligence test | — | 68,614 individuals, 100.0 % Male samples |
Mean = 58.39 years Sd = 8.36 years |
European | — | UKB | — |
| PSS009299 | — | — | 17,764 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS001295 | — | — | [
|
— | European | — | AGDS | — |
| PSS001296 | — | — | [
|
— | European | — | AGDS | — |
| PSS001297 | — | — | [
|
— | European | — | AGDS | — |
| PSS001298 | — | — | [
|
— | European | — | AGDS | — |
| PSS001299 | — | — | [
|
— | European | — | AGDS | — |
| PSS001300 | — | — | [
|
— | European | — | AGDS | — |
| PSS001301 | — | — | [
|
— | European | — | AGDS | — |
| PSS001302 | — | — | [
|
— | European | — | AGDS | — |
| PSS001303 | — | — | [
|
— | European | — | AGDS | — |
| PSS001304 | — | — | [
|
— | European | — | AGDS | — |
| PSS001305 | — | — | [
|
— | European | — | AGDS | — |
| PSS001306 | — | — | [
|
— | European | — | AGDS | — |
| PSS001307 | — | — | [
|
— | European | — | AGDS | — |
| PSS001308 | — | — | [
|
— | European | — | AGDS | — |
| PSS001309 | — | — | [
|
— | European | — | AGDS | — |
| PSS001310 | — | — | [
|
— | European | — | AGDS | — |
| PSS001311 | — | — | [
|
— | European | — | AGDS | — |
| PSS001312 | — | — | [
|
— | European | — | AGDS | — |
| PSS001313 | — | — | [
|
— | European | — | AGDS | — |
| PSS001314 | — | — | [
|
— | European | — | AGDS | — |
| PSS001315 | — | — | [
|
— | European | — | AGDS | — |
| PSS001316 | — | — | [
|
— | European | — | AGDS | — |
| PSS001317 | — | — | [
|
— | European | — | AGDS | — |
| PSS001318 | — | — | [
|
— | European | — | AGDS | — |
| PSS001319 | — | — | [
|
— | European | — | AGDS | — |
| PSS001320 | — | — | [
|
— | European | — | AGDS | — |
| PSS000250 | — | — | [
|
— | European | — | 15 cohorts
|
Part of PGC29 (PMID: 29700475) |
| PSS001321 | — | — | [
|
— | European | — | AGDS | — |
| PSS001323 | — | — | [
|
— | European | — | AGDS | — |
| PSS001324 | — | — | [
|
— | European | — | AGDS | — |
| PSS001325 | — | — | [
|
— | European | — | AGDS | — |
| PSS001326 | — | — | [
|
— | European | — | AGDS | — |
| PSS001327 | — | — | [
|
— | European | — | AGDS | — |
| PSS001328 | — | — | [
|
— | European | — | AGDS | — |
| PSS001329 | — | — | [
|
— | European | — | AGDS | — |
| PSS001330 | — | — | [
|
— | European | — | AGDS | — |
| PSS001331 | — | — | [
|
— | European | — | AGDS | — |
| PSS001332 | — | — | [
|
— | European | — | AGDS | — |
| PSS001333 | — | — | [
|
— | European | — | AGDS | — |
| PSS001334 | — | — | [
|
— | European | — | AGDS | — |
| PSS001335 | — | — | [
|
— | European | — | AGDS | — |
| PSS001336 | — | — | [
|
— | European | — | AGDS | — |
| PSS001337 | — | — | [
|
— | European | — | AGDS | — |
| PSS001338 | — | — | [
|
— | European | — | AGDS | — |
| PSS001339 | — | — | [
|
— | European | — | AGDS | — |
| PSS001340 | — | — | [
|
— | European | — | AGDS | — |
| PSS001341 | — | — | [
|
— | European | — | AGDS | — |
| PSS001342 | — | — | [
|
— | European | — | AGDS | — |
| PSS001343 | — | — | [
|
— | European | — | AGDS | — |
| PSS001344 | — | — | [
|
— | European | — | AGDS | — |
| PSS001345 | — | — | [
|
— | European | — | AGDS | — |
| PSS001346 | — | — | [
|
— | European | — | AGDS | — |
| PSS001347 | — | — | [
|
— | European | — | AGDS | — |
| PSS001348 | — | — | [
|
— | European | — | AGDS | — |
| PSS001349 | — | — | [
|
— | European | — | AGDS | — |
| PSS001350 | — | — | [
|
— | European | — | AGDS | — |
| PSS001351 | — | — | [
|
— | European | — | AGDS | — |
| PSS001352 | — | — | [
|
— | European | — | AGDS | — |
| PSS001353 | — | — | [
|
— | European | — | AGDS | — |
| PSS001354 | — | — | [
|
— | European | — | AGDS | — |
| PSS001355 | — | — | [
|
— | European | — | AGDS | — |
| PSS001356 | — | — | [
|
— | European | — | AGDS | — |
| PSS001357 | — | — | [
|
— | European | — | AGDS | — |
| PSS001358 | — | — | [
|
— | European | — | AGDS | — |
| PSS001359 | — | — | [
|
— | European | — | AGDS | — |
| PSS001360 | — | — | [
|
— | European | — | AGDS | — |
| PSS001361 | — | — | [
|
— | European | — | AGDS | — |
| PSS001362 | — | — | [
|
— | European | — | AGDS | — |
| PSS001363 | — | — | [
|
— | European | — | AGDS | — |
| PSS001364 | — | — | [
|
— | European | — | AGDS | — |
| PSS001365 | — | — | [
|
— | European | — | AGDS | — |
| PSS001366 | — | — | [
|
— | European | — | AGDS | — |
| PSS001367 | — | — | [
|
— | European | — | AGDS | — |
| PSS001368 | — | — | [
|
— | European | — | AGDS | — |
| PSS001369 | — | — | [
|
— | European | — | AGDS | — |
| PSS001370 | — | — | [
|
— | European | — | AGDS | — |
| PSS001371 | — | — | [
|
— | European | — | AGDS | — |
| PSS001372 | — | — | [
|
— | European | — | AGDS | — |
| PSS001373 | — | — | [
|
— | European | — | AGDS | — |
| PSS001374 | — | — | [
|
— | European | — | AGDS | — |
| PSS001375 | — | — | [
|
— | European | — | AGDS | — |
| PSS001376 | — | — | [
|
— | European | — | AGDS | — |
| PSS001377 | — | — | [
|
— | European | — | AGDS | — |
| PSS001378 | — | — | [
|
— | European | — | AGDS | — |
| PSS001379 | — | — | [
|
— | European | — | AGDS | — |
| PSS001380 | — | — | [
|
— | European | — | AGDS | — |
| PSS001381 | — | — | [
|
— | European | — | AGDS | — |
| PSS001382 | — | — | [
|
— | European | — | AGDS | — |
| PSS001383 | — | — | [
|
— | European | — | AGDS | — |
| PSS001384 | — | — | [
|
— | European | — | AGDS | — |
| PSS001385 | — | — | [
|
— | European | — | AGDS | — |
| PSS001386 | — | — | [
|
— | European | — | AGDS | — |
| PSS001387 | — | — | [
|
— | European | — | AGDS | — |
| PSS001388 | — | — | [
|
— | European | — | AGDS | — |
| PSS001389 | — | — | [
|
— | European | — | AGDS | — |
| PSS001390 | — | — | [
|
— | European | — | AGDS | — |
| PSS001391 | — | — | [
|
— | European | — | AGDS | — |
| PSS001392 | — | — | [
|
— | European | — | AGDS | — |
| PSS001393 | — | — | [
|
— | European | — | AGDS | — |
| PSS001394 | — | — | [
|
— | European | — | AGDS | — |
| PSS001395 | — | — | [
|
— | European | — | AGDS | — |
| PSS001396 | — | — | [
|
— | European | — | AGDS | — |
| PSS001397 | — | — | [
|
— | European | — | AGDS | — |
| PSS001398 | — | — | [
|
— | European | — | AGDS | — |
| PSS001399 | — | — | [
|
— | European | — | AGDS | — |
| PSS001400 | — | — | [
|
— | European | — | AGDS | — |
| PSS001401 | — | — | [
|
— | European | — | AGDS | — |
| PSS001402 | — | — | [
|
— | European | — | AGDS | — |
| PSS001403 | — | — | [
|
— | European | — | AGDS | — |
| PSS001404 | — | — | [
|
— | European | — | AGDS | — |
| PSS001405 | — | — | [
|
— | European | — | AGDS | — |
| PSS001406 | — | — | [
|
— | European | — | AGDS | — |
| PSS001407 | — | — | [
|
— | European | — | AGDS | — |
| PSS001408 | — | — | [
|
— | European | — | AGDS | — |
| PSS001409 | — | — | [
|
— | European | — | AGDS | — |
| PSS001410 | — | — | [
|
— | European | — | AGDS | — |
| PSS001411 | — | — | [
|
— | European | — | AGDS | — |
| PSS001412 | — | — | [
|
— | European | — | AGDS | — |
| PSS001413 | — | — | [
|
— | European | — | AGDS | — |
| PSS001414 | — | — | [
|
— | European | — | AGDS | — |
| PSS001415 | — | — | [
|
— | European | — | AGDS | — |
| PSS001416 | — | — | [
|
— | European | — | AGDS | — |
| PSS001417 | — | — | [
|
— | European | — | AGDS | — |
| PSS001418 | — | — | [
|
— | European | — | AGDS | — |
| PSS001419 | — | — | [
|
— | European | — | AGDS | — |
| PSS001420 | — | — | [
|
— | European | — | AGDS | — |
| PSS001421 | — | — | [
|
— | European | — | AGDS | — |
| PSS001422 | — | — | [
|
— | European | — | AGDS | — |
| PSS001423 | — | — | [
|
— | European | — | AGDS | — |
| PSS001424 | — | — | [
|
— | European | — | AGDS | — |
| PSS001425 | — | — | [
|
— | European | — | AGDS | — |
| PSS001426 | — | — | [
|
— | European | — | AGDS | — |
| PSS001427 | — | — | [
|
— | European | — | AGDS | — |
| PSS001428 | — | — | [
|
— | European | — | AGDS | — |
| PSS001429 | — | — | [
|
— | European | — | AGDS | — |
| PSS001430 | — | — | [
|
— | European | — | AGDS | — |
| PSS001431 | — | — | [
|
— | European | — | AGDS | — |
| PSS001432 | — | — | [
|
— | European | — | AGDS | — |
| PSS001433 | — | — | [
|
— | European | — | AGDS | — |
| PSS001434 | — | — | [
|
— | European | — | AGDS | — |
| PSS001435 | — | — | [
|
— | European | — | AGDS | — |
| PSS001436 | — | — | [
|
— | European | — | AGDS | — |
| PSS001437 | — | — | [
|
— | European | — | AGDS | — |
| PSS001438 | — | — | [
|
— | European | — | AGDS | — |
| PSS001439 | — | — | [
|
— | European | — | AGDS | — |
| PSS001440 | — | — | [
|
— | European | — | AGDS | — |
| PSS001441 | — | — | [
|
— | European | — | AGDS | — |
| PSS001442 | — | — | [
|
— | European | — | AGDS | — |
| PSS001443 | — | — | [
|
— | European | — | AGDS | — |
| PSS001444 | — | — | [
|
— | European | — | AGDS | — |
| PSS001322 | — | — | [
|
— | European | — | AGDS | — |
| PSS008401 | — | — | 1,055 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS009073 | — | — | 3,729 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS010156 | — | — | 4,382 individuals, 50.0 % Male samples |
Mean = 9.94 years | Not reported | — | NR | ABCD |
| PSS008627 | — | — | 5,989 individuals | — | European | Italy (South Europe) | UKB | — |